Business
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment\nExpect to finalize IND-enabling studies for PH-894 in the second half of 2022\nMARLBOROUGH, Mass., May 12, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg\n\"We are pleased enrollment is open for our first-in-human clinical trial for PH-762 at the Gustave Roussy Institute, one of the largest cancer centers in Europe. This study will evaluate the safety, tolerability, pharmacokinetics and checkpoint anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma. The clinical study will feature a dose escalation of PH-762 with top-line data from the first group of patients expected in the first quarter of 2023,\" said Dr. Geert Cauwenbergh, Principal Executive Officer of Phio. \"In addition, the new preclinical data we recently presented at the AACR Annual Meeting shows the potential of PH-894 to be used in treating patients who do not respond to anti-PD-1 therapy, or patients who progress after initially responding to treatment with checkpoint inhibitors. The reaction of the investment community when this data was presented, reinforces the relevance of a compound like PH-894, an INTASYL compound specifically targeting BRD4, in patients who may not respond or relapse after PD-1 therapy. We expect to finalize IND-enabling studies for PH-894 in the second half of 2022,\" concluded Dr. Cauwenbergh.\nQuarter in Review and Recent Corporate Updates\nEnrollment open for the Company's Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma.Presented new in vivo data at the AACR Annual Meeting 2022 that provide a strong rationale for the clinical use of PH-894, a BRD4-targeting, self-delivering RNAi, as a monotherapy, as well as in combination with systemic PD-1 therapy.Continue to develop PH-3861, a dual-targeting INTASYL towards PD-1 and BR...